Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against burkholderia pseudomallei infection in BALB/c mice

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 675-683

  Puangpetch, Apichaya ^a,b   Anderson, Robert ^c   Huang, Yan Y ^c   Sermswan, Rasana W ^a,b   Chaicumpa, Wanpen ^d   Sirisinha, Stitaya ^e   Wongratanacheewina, Surasakdi ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c DALHOUSIE UNIVERSITY   (Canada)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Mahidol University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CPG OLIGODEOXYNUCLEOTIDE; DIOLEOYLPHOSPHATIDYLCHOLINE; GAMMA INTERFERON; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BURKHOLDERIA PSEUDOMALLEI; CELL LEVEL; CONTROLLED STUDY; IMMUNOSTIMULATION; MACROPHAGE FUNCTION; MALE; MELIOIDOSIS; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL VACCINES; BURKHOLDERIA PSEUDOMALLEI; DISEASE MODELS, ANIMAL; HUMANS; LIPOSOMES; MACROPHAGES; MALE; MELIOIDOSIS; MICE; MICE, INBRED BALB C; NEUTROPHILS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84860334366     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05545-11     Document Type: Article

References (48)

1. Ashdown LR. 1979. An improved screening technique for isolation of Pseudomonas pseudomallei from clinical specimens. Pathology 11:293-297. (Pubitemid 9229178)
2. Boxio R, Bossenmeyer-Pourie C, Steinckwich N, Dournon C, Nusse O. 2004. Mouse bone marrow contains large numbers of functionally competent neutrophils. J. Leukoc. Biol. 75:604-611. (Pubitemid 38405651)
3. Breitbach K, et al. 2006. Role of inducible nitric oxide synthase and NADPH oxidase in early control of Burkholderia pseudomallei infection in mice. Infect. Immun. 74:6300-6309. (Pubitemid 44657411)
4. Breitbach K, Kohler J, Steinmetz I. 2008. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl. 1):S89-S94.
5. Cheng AC, Currie BJ. 2005. Melioidosis: Epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416. (Pubitemid 40548298)
6. Chua KL, Chan YY, Gan YH. 2003. Flagella are virulence determinants of Burkholderia pseudomallei. Infect. Immun. 71:1622-1629. (Pubitemid 36368689)
7. Cowdery JS, Chace JH, Yi AK, Krieg AM. 1996. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:4570-4575. (Pubitemid 26174435)
8. Currie BJ, Fisher DA, Anstey NM, Jacups SP. 2000. Melioidosis: Acute and chronic disease, relapse and re-activation. Trans. R. Soc. Trop. Med. Hyg. 94:301-304. (Pubitemid 30406565)
9. Das M, Chopra AK, Cantu JM, Peterson JW. 1998. Antisera to selected outer membrane proteins of Vibrio cholerae protect against challenge with homologous and heterologous strains of V. cholerae. FEMS Immunol. Med. Microbiol. 22:303-308. (Pubitemid 29010287)
10. Deng JC, et al. 2004. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J. Immunol. 173: 5148-5155. (Pubitemid 39402952)
11. Druar C, et al. 2008. Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents. FEMS Immunol. Med. Microbiol. 52:78-87.
12. Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ. 2007. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J. Infect. Dis. 195:99-107. (Pubitemid 44958231)
13. Easton A, et al. 2011. Combining vaccination and post exposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J. Infect. Dis. 204:636-644.
14. Egan AM, Gordon DL. 1996. Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect. Immun. 64:4952-4959. (Pubitemid 26403947)
15. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. 1999. Bacterial DNA containing CpG motifs stimulates lymphocytedependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162:2291-2298. (Pubitemid 29288853)
16. Gao JJ, et al. 1999. Cutting edge: Bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J. Immunol. 163:4095-4099. (Pubitemid 29474469)
17. Gursel M, Tunca S, Ozkan M, Ozcengiz G, Alaeddinoglu G. 1999. Immunoadjuvant action of plasmidDNAin liposomes. Vaccine 17:1376-1383.
18. + T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J. Infect. Dis. 194:1241-1248. (Pubitemid 44630969)
19. Hara Y, Mohamed R, Nathan S. 2009. Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets. PLoS One 4:e6496.
20. Harland DN, et al. 2007. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect. Immun. 75:4173-4180. (Pubitemid 47206316)
21. Hoppe I, et al. 1999. Characterization of a murine model of melioidosis: Comparison of different strains of mice. Infect. Immun. 67:2891-2900. (Pubitemid 29244705)
22. Jaafari MR, et al. 2006. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24:5708-5717. (Pubitemid 43928184)
23. Jones SM, Ellis JF, Russell P, Griffin KF, Oyston PC. 2002. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J. Med. Microbiol. 51:1055-1062. (Pubitemid 36020726)
24. Kirby C, Gregoriadis G. 1984. Dehydration-rehydration vesicles: A simple method for high yield drug entrapment in liposomes. Biotechnology 2:979-984. (Pubitemid 15090594)
25. Klinman DM, Currie D, Gursel I, Verthelyi D. 2004. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199:201-216. (Pubitemid 38736773)
26. Krieg AM. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760. (Pubitemid 34293438)
27. Krieg AM, Love-Homan L, Yi AK, Harty JT. 1998. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161:2428-2434. (Pubitemid 28397058)
28. Lauw FN, et al. 1999. Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. J. Infect. Dis. 180:1878-1885.
29. Leelarasamee A, Bovornkitti S. 1989. Melioidosis: Review and update. Rev. Infect. Dis. 11:413-425.
30. Limmathurotsakul D, et al. 2010. Increasing incidence of human melioidosis in Northeast Thailand. Am. J. Trop. Med. Hyg. 82:1113-1117.
31. MacMicking J, Xie QW, Nathan C. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-350. (Pubitemid 27169284)
32. McCluskie MJ, Davis HL. 2000. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19:413-422.
33. Miyagi K, Kawakami K, Saito A. 1997. Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia pseudomallei. Infect. Immun. 65:4108-4113. (Pubitemid 27422066)
34. Rozak DA, et al. 2010. CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J. Immune Based Ther. Vaccines 8:2.
35. Santanirand P, Harley VS, Dance DA, Drasar BS, Bancroft GJ. 1999. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 67:3593-3600. (Pubitemid 29291534)
36. Sarkar-Tyson M, et al. 2007. Polysaccharides and virulence of Burkholderia pseudomallei. J. Med. Microbiol. 56:1005-1010. (Pubitemid 47262660)
37. Stevens MP, et al. 2004. Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology 150:2669-2676. (Pubitemid 39173270)
38. Suzuki Y, et al. 2004. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64:8754-8760. (Pubitemid 39552093)
39. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4:145-160. (Pubitemid 40282557)
40. Utaisincharoen P, Anantagool N, Limposuwan K, Chaisuriya P, Sirisinha S. 2003. Involvement of beta interferon in enhancing inducible nitric oxide synthase production and antimicrobial activity of Burkholderia pseudomallei-infected macrophages. Infect. Immun. 71:3053-3057. (Pubitemid 36637526)
41. Utaisincharoen P, Tangthawornchaikul N, Kespichayawattana W, Chaisuriya P, Sirisinha S. 2001. Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: A possible mechanism of evading macrophage killing. Microbiol. Immunol. 45:307-313. (Pubitemid 32367620)
42. Weighardt H, et al. 2000. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J. Immunol. 165:4537-4543.
43. Weiser JN, Gotschlich EC. 1991. Outer membrane protein A (OmpA) contributes to serum resistance and pathogenicity of Escherichia coli K-1. Infect. Immun. 59:2252-2258.
44. White NJ. 2003 Melioidosis. Lancet 361:1715-1722. (Pubitemid 36577448)
45. Wiersinga WJ, van der Poll T. 2009. Immunity to Burkholderia pseudomallei. Curr. Opin. Infect. Dis. 22:102-108.
46. Wiersinga WJ, Wieland CW, Roelofs JJ, van der Poll T. 2008. MyD88 dependent signaling contributes to protective host defense against Burkholderia pseudomallei. PLoS One 3:e3494.
47. Wongratanacheewin S, et al. 2004. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 72:4494-4502. (Pubitemid 38989307)
48. Yamamoto S, et al. 1992. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 148:4072-4076.